Akèy › Limfòm selil-T kutane
Etid klinik pou Limfòm selil-T kutane ap rekrite nan Etazini
30 etid pou Limfòm selil-T kutane ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY9 etid
- Baldwin Park, CA8 etid
- Boston, MA5 etid
- Houston, TX5 etid
- New Haven, CT4 etid
- Tampa, FL3 etid
- Chicago, IL3 etid
- Durham, NC3 etid
- Ann Arbor, MI3 etid
- Columbus, OH3 etid
- Rochester, MN3 etid
- Scottsdale, AZ3 etid
Pa eta
- Arizona3 etid
- Connecticut4 etid
- Florid3 etid
- Illinois3 etid
- Kalifòni8 etid
- Massachusetts5 etid
- Michigan3 etid
- Minnesota3 etid
- New York10 etid
- North Carolina3 etid
- Ohio4 etid
- Pennsylvania4 etid
- Texas5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT01087333A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06854653Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04930653A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 24, 2026 · NCT07055477Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT03011814A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT04045470A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT06698822Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT05956041Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 89 · Tout sèks · Mizajou May 1, 2026 · NCT03932279Photopheresis in Early-stage Mycosis Fungoides
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 27, 2026 · NCT05680558Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 14, 2026 · NCT05996185Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 1, 2026 · NCT07047885Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2026 · NCT04848064A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 4, 2026 · NCT05296304Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT04670874Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Dec 30, 2025 · NCT00177268Amping up With PemJAK
Ap rekriteFaz 2
Laj 18 a 95 · Tout sèks · Mizajou Dec 16, 2025 · NCT07283822Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.